Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Verve Therapeutics selects VERVE-101 as its lead gene editing therapy candidate

Jan. 13, 2021

Ultragenyx updates gene therapy program progress

Jan. 11, 2021

Indian researchers patent new lipoxygenase inhibitors

Jan. 11, 2021

REMD reports phase II topline data on volagidemab in type 1 diabetes

Jan. 8, 2021

Penciling in the right base corrects progeria mutation

Jan. 8, 2021

HELIOS-A phase III study of vutrisiran meets its primary and secondary endpoints

Jan. 8, 2021

FDA clears IND for phase I/II study of FBX-101 in patients with Krabbe disease

Jan. 5, 2021

FDA clears IND for PBGM-01 for infantile GM1 gangliosidosis

Jan. 4, 2021

Final results from phase III BRIDGE study of pegunigalsidase alfa for Fabry disease

Dec. 30, 2020

Lysogene reports biomarker data from AAVance trial of LYS-SAF-302 for MPS IIIA

Dec. 29, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...